Literature DB >> 10919898

Capnocytophaga keratitis.

G Alexandrakis1, L A Palma, D Miller, E C Alfonso.   

Abstract

PURPOSE: To review the clinical course, treatment, and visual outcomes of keratitis caused by the gram negative rod CAPNOCYTOPHAGA:
DESIGN: Retrospective, noncomparative case series. PARTICIPANTS: Ten patients with culture-proven unilateral CAPNOCYTOPHAGA: keratitis examined at the Bascom Palmer Eye Institute between January 1, 1989, and December 31, 1998. INTERVENTION: All patients underwent standard diagnostic microbiologic evaluation, and topical antimicrobial therapy was instituted. A penetrating keratoplasty or enucleation was performed in some patients. MAIN OUTCOME MEASURES: The changes in visual acuity and clinical response to antimicrobial therapy.
RESULTS: Predisposing factors were present in all patients. Cultures identified CAPNOCYTOPHAGA: species at a mean of 7.5 days. Initial topical treatment consisted of an aminoglycoside and vancomycin in four patients, a quinolone or aminoglycoside alone in two patients each, and ofloxacin with vancomycin or tobramycin with ceftazidime in one patient each. After the microbiologic identification of CAPNOCYTOPHAGA:, treatment in four patients was changed to intensive, topical clindamycin. Five of the 10 eyes were medically cured (3 of these eyes underwent penetrating keratoplasty for corneal scarring), and 5 eyes required enucleation. The indications for enucleation included persistent infection with development of endophthalmitis or blind, painful eye. Five of the 10 eyes achieved 20/80 or better final visual acuity. Four of these five eyes were treated with topical clindamycin.
CONCLUSIONS: Important factors in achieving a good visual outcome in CAPNOCYTOPHAGA: keratitis include early microbiologic identification and intensive therapy with topical clindamycin. CAPNOCYTOPHAGA: should be included in the differential diagnosis of bacterial keratitis in patients with suggestive predisposing factors or with protracted keratitis unresponsive to treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10919898     DOI: 10.1016/s0161-6420(00)00227-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Capnocytophaga lung abscess in a patient with metastatic neuroendocrine tumor.

Authors:  Raghu Thirumala; Urania Rappo; N Esther Babady; Mini Kamboj; Mohit Chawla
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Capnocytophaga bacteraemia following rituximab treatment.

Authors:  Elisheva Pokroy-Shapira; Shachaf Shiber; Yair Molad
Journal:  BMJ Case Rep       Date:  2012-08-13

Review 3.  Capnocytophaga canimorsus blebitis: case report and review of literature.

Authors:  Michael C Yang; John Ling; Sameh Mosaed
Journal:  BMC Ophthalmol       Date:  2021-01-26       Impact factor: 2.209

4.  Capnocytophaga Keratitis: Clinical Presentation and Use of Metagenomic Deep Sequencing for Diagnosis.

Authors:  Gerami D Seitzman; Praneetha Thulasi; Armin Hinterwirth; Cindi Chen; Jessica Shantha; Thuy Doan
Journal:  Cornea       Date:  2019-02       Impact factor: 2.651

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.